Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $43.80

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has earned an average rating of "Moderate Buy" from the five research firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $43.80.

INO has been the subject of several recent analyst reports. Oppenheimer lowered their price target on Inovio Pharmaceuticals from $40.00 to $33.00 and set an "outperform" rating for the company in a report on Monday, August 12th. Royal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $8.00 to $7.00 and set a "sector perform" rating for the company in a report on Friday, October 4th. Finally, HC Wainwright reissued a "neutral" rating and issued a $15.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, July 15th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Inovio Pharmaceuticals in the first quarter valued at approximately $1,482,000. Cornercap Investment Counsel Inc. purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $184,000. American Century Companies Inc. increased its position in shares of Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company's stock worth $255,000 after purchasing an additional 12,100 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Inovio Pharmaceuticals during the second quarter worth approximately $661,000. Finally, Signature Estate & Investment Advisors LLC purchased a new stake in shares of Inovio Pharmaceuticals during the second quarter worth approximately $88,000. 26.79% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Price Performance

INO remained flat at $5.70 on Wednesday. The company's stock had a trading volume of 242,531 shares, compared to its average volume of 407,956. The company has a 50-day simple moving average of $6.43 and a two-hundred day simple moving average of $8.83. Inovio Pharmaceuticals has a 52 week low of $3.89 and a 52 week high of $14.75. The stock has a market cap of $147.69 million, a PE ratio of -1.54 and a beta of 0.82.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the previous year, the business earned ($1.56) EPS. On average, research analysts forecast that Inovio Pharmaceuticals will post -4.64 earnings per share for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.